Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#2845 Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading?

Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kaemmerer D, Trwznik M, Hörsch D, Baum R, Hommann M,

Keywords: Surgery, Primary tumor, PRRT, Grading,

#2045 Perioperative Outcomes of Surgery for Pancreatic Neuroendocrine Neoplasms in Germany

Introduction: The incidence of pancreatic neuroendocrine neoplasms(pNEN) is increasing and the perioperative outcomes of specialized centers are favourable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Mintziras I, Werner J, Keck T, Hommann M, Germer C,

Keywords: pancreatic neuroendocrine neoplasms, surgical resection, StuDoQ|pancreas registry,

#2044 Are Current ENETS Guidelines for Surgery of Small (< 2cm) Pancreatic Neuroendocrine Neoplasms Implemented in German Surgical Community?

Introduction: According to ENETS guidelines small(

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Mintziras I, Werner J, Keck T, Hommann M, Germer C,

Keywords: small (<2cm) pancreatic neuroendocrine tumors, surgical resection, StuDoQ|pancreas registry,

#1827 Primary Tumor Resection Results in Superior Overall Survival after Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Neoplasms

Introduction: Peptide receptor radionuclide therapy (PRRT) is an highly effective therapeutic option to treat advanced neuroendocrine neoplasms (NEN). However, it is still unclear whether resection of primary tumors improves overall survival (OS) after PRRT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kaemmerer D

Authors: Kaemmerer D, Twrznik M, Hommann M, Hörsch D, Baum R,

Keywords: PRRT, surgery,

#1570 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years

Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Niepsch K, Kaemmerer D, Hommann M,

Keywords: PRRT, Survival, PET/CT,